Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

116.40 -0.43 (-0.37%)
Official Closing Price Updated: 7:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
3 Coronavirus Stocks To Buy In December
Moderna is the leading company in the development of messenger RNA-based medicines and vaccines to treat infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune... 
Via Talk Markets
Exposures COVID-19
3 Healthcare Stocks for Long-Term Dividend Growth
Dividend investors face a variety of choices. We like healthcare stocks for many reasons, such as long-term earnings growth. 
Via InvestorPlace
Expert Ratings For Abbott Laboratories
Within the last quarter, Abbott Laboratories (NYSE:ABT) has observed the follo... 
Via Benzinga
Here's How Much $100 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today
Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 12.02% on an annualized basis. Buying $100.00 In ABT: 5 years ago, an investor could have... 
Via Benzinga
This Biotech CEO Is Trying To Cure His Son's Rare Disease
Few questions stump Tim Walbert. But the Horizon Therapeutics CEO is still working to answer one of them from his son. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE: 
Via Benzinga
Watch for Continued Gains in Shares of Abbott Laboratories
Shares of Abbott Laboratories (NYSE: ABT) traded today at $132.41, eclipsing its 12-month high. Approximately 1.4 million shares have changed hands today, as compared to an... 
Via Benzinga
How Did Healthcare Stocks Perform Over This Volatile Month?
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%. 
Via Talk Markets
Watch for Continued Gains in Shares of Abbott Laboratories
Shares of Abbott Laboratories (NYSE: ABT) traded today at $132.41, eclipsing its 12-month high. Approximately 1.4 million shares have changed hands today, as compared to an... 
Via Benzinga
7 Stocks to Buy to Give Your Portfolio a Booster Shot
With the new strain already reported in the U.S., it’s time to consider some adjustments to your portfolio. 
Via InvestorPlace
Exposures COVID-19
Abbott Labs Stock Climbs Into Top-Performers Group Amid Continued double- and triple-digit Profit, Sales Growth
A Relative Strength Rating upgrade for Abbott Laboratories shows improving technical performance. 
Via Investor's Business Daily
Even Good Penny Stocks Like Senseonics Aren’t Always Profitable
Its latest implanted sensor lasts six months, but SENS stock faces competition from Dexcom, Abbott Labs and potentially one big name in tech. 
Via InvestorPlace
Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests
President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened... 
Via Benzinga
Exposures COVID-19
Notable Abbott Laboratories Insider Trades $5.5M In Company Stock
Gregory A Ahlberg, Insider at Abbott Laboratories (NYSE:ABT), made a large buy and sell of company shares on November 15, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Danaher Stock Shows Renewed Strength, Earning Key Rating Hike Amid Rising Profits, Sales
A Relative Strength Rating upgrade for Danaher shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Better Buy: DexCom or Abbott Labs?
Abbott's the heavyweight, and DexCom is the formidable challenger. 
Via The Motley Fool
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
Johnson & Johnson will split its consumer health unit into a publicly traded company. 
Via Investor's Business Daily
2 Dividend Aristocrats That Could Announce Generous Rate Hikes in December
Buy now to take advantage of what will likely be higher yields to come. 
Via The Motley Fool
10 S&P 500 Stocks to Buy After Winning in Q3
Earnings reports for S&P 500 stocks have been exceptionally good so far. Here are 10 stocks to buy that have delivered in Q3. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Lilly Stock Receives Key IBD Stock Rating Upgrade; Looking To Extend Its Long Run Higher
Lilly stock's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks. 
Via Investor's Business Daily
7 Dividend Aristocrat Stocks That Should Grace Your Portfolio
You get a lot more more from dividend aristocrat stocks than just a rock-solid dividend. They also promise solid, long-term growth. 
Via InvestorPlace
Topics Economy
Exposures Economy
Vice President Of Abbott Laboratories Makes $1.0M Sale
Philip P Boudreau, Vice President at Abbott Laboratories (NYSE:ABT), made a large insider sell on October 25, according to a new SEC filing. What Happened: A Form 4 filing from... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Edwards Topples As Full-Year Guidance Comes In Light After Mixed Quarter
The company retained guidance for adjusted profit of $2.07-$2.27, missing the midpoint of analysts' view. 
Via Investor's Business Daily
Where Abbott Laboratories Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2021
Upgrades According to Credit Suisse, the prior rating for Mercer International Inc (NASDAQ: 
Via Benzinga
Got $5,000? These 2 Unstoppable Stocks Are No-Brainer Buys
Both are great places to park your money for years. 
Via The Motley Fool
Kimberly-Clark's Earnings Remind Investors that Inflation and Supply Chain Issues are Still a Major Theme
This week is a big one for earnings, not just because of the big names reporting but because of the large number of earnings announcements. Investors can expect the themes of... 
Via Benzinga
Will Tech Stocks Derail the 3Q21 Earnings Rally?
S&P 500 equities continued to post robust 3rd quarter earnings reports, staying on track to grow EPS by 32.7% year-over-year. Over 84% of those reporting topped analysts’ forecasts. The damage from a... 
Via Talk Markets
Topics Stocks
Exposures US Equities
AbbVie: A Healthy Idea For Retirement Portfolios
The healthcare industry is among the cheapest sectors in today's market, and this pandemic has validated its importance for the economy and our overall well-being. Over the next decade, we will see... 
Via Talk Markets
Topics Economy Retirement
Exposures Economy Pension
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.